Eltrombopag and high-dose dexamethasone as first-line treatment in children with newly diagnosed primary immune thrombocytopenia
Monika Richert-Przygońska,
Dominika Kołuda,
Mariusz Wysocki
Abstract:Introduction: Novel treatment strategies for newly diagnosed immune thrombocytopenia (ndITP) pediatric patients are required.
Material and methods:The aim of this study was to analyze the safety and efficacy of eltrombopag and dexamethasone when used as the first-line treatment in children with ndITP. Inclusion criteria: age 5-18 years, and ndITP with bleeding manifestation. Treatment course: 28 days of eltrombopag with oral dexamethasone in three repeated courses.Results: A complete response was achieved in 9… Show more
Set email alert for when this publication receives citations?
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.